Table 3.
Summary of included studies: case studies
| Study | Clinical population | Total n | Design | Trial length | CBD dose (mg) and approx. mg/kg/da | Route of admin. | CBD source | Resultsb: Primary endpoint(s) | + effect | Side effects |
|---|---|---|---|---|---|---|---|---|---|---|
| Kaplan, 2017 33 | Refractory seizures in Sturge–Weber syndrome, children | 5 | Case‐series | 14 wk | 5–25 mg/kg/d | Oral solution | GW | Decreases in seizure frequency | Yes | Mild |
| Warren, 2017 34 | Brain tumour related epilepsy, aged 17–40 y | 3 | Case series | 2–10 mo | 10–50 mg/kg/d | Oral | GW | Improvement in seizure frequency (n = 2) and severity (n = 3) | Yes | Diarrhoea |
| Gofshteyn, 2017 35 | Febrile infection‐related epilepsy syndrome, children | 7 | Open‐label case series | Acute and up to 48 weeks | 15–25 mg/kg/d | Oral solution | GW | Improvements in frequency and duration of seizures | Yes | Dizziness, decreased appetite, weight loss |
| Shannon, 2016 10 | Anxiety and insomnia in PTSD, child | 1 | Case report | 5 mo | 25 mg/d (0.6 mg/kg/d) | Oral capsule and spray | CannaVest Corp | Increased sleep quality and duration, and decreased anxiety secondary to PTSD | Yes | None observed |
| Saade, 2015 36 | Seizures, 10‐month old infant | 1 | Case report | 6 mo | 25 mg/kg/d | Oral solution | GW | Substantial reductions in seizures | Yes | None reported |
| Chagas, 2014 37 | RBD in Parkinson's disease, adults | 4 | Case series | 6 wk | 75 mg/d (1.25 mg/kg/d) | NA | NA | Substantial reduction in RBD‐associated events compared to baseline | Yes | None reported |
| Crippa, 2013 38 | Cannabis dependency, adult | 1 | Case report | 10 d | 300 mg/d increased to 600 mg/d (5–10 mg/kg/d) | Oral capsule | THC | Absence of withdrawal symptoms | Yes | None reported |
| Zuardi, 2010 39 | Bipolar disorder, adults | 2 | Case series | 30 d | 600 mg/d increased to 1200 mg/d (20 mg/kg/d) | Oral | STI and THC | CBD was ineffective for manic episode | No | None observed |
| Zuardi, 1995 40 | Schizophrenia, adult | 1 | Case report | 4 wk | 1500 mg/d (25 mg/kg/d) | Oral capsules | NA | Improvements in psychiatric ratings | Yes | Well tolerated; none reported |
| Zuardi, 2006 41 | Treatment‐resistant schizophrenia, adults | 3 | Case series | 30 d | 40 mg/d, increased to 1280 mg/d (21.3 mg/kg/d) | Oral | GW | 1 patient showed mild improvement to baseline and discontinuing treatment worsened symptoms | No | Well tolerated; none observed |
| Snider, 1985 42 | Parkinson's disease, adult | 1 | Case report | 4 wk | 100–400 mg/d (3.3 mg/kg/d) | Oral | NA | Improvement of dyskinesia up to 200 mg/d, worsening of Parkinson disease symptoms with 300–400 mg/d | Mixed | Dizziness, drowsiness, increased Parkinson symptoms |
| Snider, 1984 43 | Meige syndrome, adult | 1 | Case report | Long‐term | Initially 100 mg/d increased to 400 mg/d (6.6 mg/kg/d) | Oral | NA | 50% improvement in spasm frequency and severity | Yes | Dry mouth, headache, sedation |
a
If not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.
b
Significant compared to placebo/control (P < .05) unless stated otherwise.
CBD, cannabidiol; GW, GW Pharmaceuticals; PTSD, post‐traumatic stress disorder; RBD, rapid eye movement sleep behaviour disorder; STI, STI Pharmaceuticals; THC, THC Pharm.